Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Drugs In Development, 2022, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.
Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 18, 13, 1, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Synovial Sarcoma - Overview
Synovial Sarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Synovial Sarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Synovial Sarcoma - Companies Involved in Therapeutics Development
Synovial Sarcoma - Drug Profiles
Synovial Sarcoma - Dormant Projects
Synovial Sarcoma - Discontinued Products
Synovial Sarcoma - Product Development Milestones
Featured News & Press Releases
Nov 11, 2021: Adaptimmune reports positive results from its pivotal SPEARHEAD-1 trial in patients with synovial sarcoma and MRCLS at CTOS
Oct 19, 2021: Foghorn Therapeutics announces presentation at Upcoming 4th Annual Targeted Protein Degradation Summit
Aug 23, 2021: Foghorn Therapeutics announces first patient dosed in first-in-human clinical trial of FHD-609
May 19, 2021: Two complete responses and response rate of 41% for people with synovial sarcoma reported at ASCO in Adaptimmune’s phase 2 SPEARHEAD-1 trial
Mar 18, 2021: Foghorn Therapeutics provides update on FHD-609
Nov 19, 2020: Durable responses with ADP-A2M4 in synovial sarcoma with confirmed responses in 44% of patients and disease control rate of 94% presented at CTOS
Oct 14, 2020: C4 Therapeutics to present at the 3rd Annual Targeted Protein Degradation Summit
Jul 23, 2020: Adaptimmune granted access to PRIority MEdicines (PRIME) regulatory support by the European Medicines Agency for ADP-A2M4 for the treatment of synovial sarcoma
Dec 03, 2019: Regenerative Medicine Advanced Therapy Designation granted by FDA to ADP-A2M4 for the treatment of Synovial Sarcoma
Nov 16, 2019: Updated data from phase 1 ADP-A2M4 trial demonstrating continued clinical benefit for people with synovial sarcoma
Sep 30, 2019: Clear Benefit for patients with synovial sarcoma demonstrated in updated data from ongoing phase 1 trial with ADP-A2M4 presented at ESMO
Sep 10, 2019: GSK to present data on its drug candidate GSK-3377794 at ESMO Congress 2019
Aug 15, 2019: OncoTherapy Science: Announcement of the initiation of Phase I study for OTSA101 in Japanese patients with synovial sarcoma
Jul 25, 2019: Adaptimmune starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
May 06, 2019: Significant clinical progress as Adaptimmune announces responses with ADP-A2M4 in synovial sarcoma and antitumor activity in other solid tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Synovial Sarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Synovial Sarcoma - Pipeline by 3SBio Inc, 2022
Synovial Sarcoma - Pipeline by Accuronix Therapeutics Inc, 2022
Synovial Sarcoma - Pipeline by Actuate Therapeutics Inc, 2022
Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, 2022
Synovial Sarcoma - Pipeline by Advenchen Laboratories LLC, 2022
Synovial Sarcoma - Pipeline by Apollomics Inc, 2022
Synovial Sarcoma - Pipeline by Astellas Pharma Inc, 2022
Synovial Sarcoma - Pipeline by BioAtla Inc, 2022
Synovial Sarcoma - Pipeline by Biogenera SpA, 2022
Synovial Sarcoma - Pipeline by C4 Therapeutics Inc, 2022
Synovial Sarcoma - Pipeline by Calithera Biosciences Inc, 2022
Synovial Sarcoma - Pipeline by CoBioRes NV, 2022
Synovial Sarcoma - Pipeline by Cue Biopharma Inc, 2022
Synovial Sarcoma - Pipeline by ENB Therapeutics LLC, 2022
Synovial Sarcoma - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Synovial Sarcoma - Pipeline by Foghorn Therapeutics Inc, 2022
Synovial Sarcoma - Pipeline by GlaxoSmithKline Plc, 2022
Synovial Sarcoma - Pipeline by Immunocore Limited, 2022
Synovial Sarcoma - Pipeline by Incyte Corp, 2022
Synovial Sarcoma - Pipeline by Inhibrx Inc, 2022
Synovial Sarcoma - Pipeline by Innovative Cellular Therapeutics Co Ltd, 2022
Synovial Sarcoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Synovial Sarcoma - Pipeline by Karyopharm Therapeutics Inc, 2022
Synovial Sarcoma - Pipeline by Lyell Immunopharma Inc, 2022
Synovial Sarcoma - Pipeline by MediGene AG, 2022
Synovial Sarcoma - Pipeline by Merck & Co Inc, 2022
Synovial Sarcoma - Pipeline by Mirati Therapeutics Inc, 2022
Synovial Sarcoma - Pipeline by Ohara Pharmaceutical Co Ltd, 2022
Synovial Sarcoma - Pipeline by OncoTherapy Science Inc, 2022
Synovial Sarcoma - Pipeline by Pfizer Inc, 2022
Synovial Sarcoma - Pipeline by Pharma Mar SA, 2022
Synovial Sarcoma - Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
Synovial Sarcoma - Pipeline by Shanghai GeneChem Co Ltd, 2022
Synovial Sarcoma - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Synovial Sarcoma - Pipeline by Tactical Therapeutics Inc, 2022
Synovial Sarcoma - Pipeline by Takara Bio Inc, 2022
Synovial Sarcoma - Pipeline by United Immunity Co Ltd, 2022
Synovial Sarcoma - Pipeline by Xiangxue Life Sciences, 2022
Synovial Sarcoma - Dormant Projects, 2022
Synovial Sarcoma - Discontinued Products, 2022
List of Figures
Number of Products under Development for Synovial Sarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
